Mitchell Slovin

Mitchell Slovin is a seasoned professional in the biopharmaceutical industry, currently serving as Senior Manager of Manufacturing Science and Technology at CRISPR Therapeutics since November 2020. In this role, Mitchell leads cross-functional teams to implement strategic development initiatives for CRISPR/Cas9 gene-edited therapies, managing global process engineers in gene-editing technologies and overseeing critical technology transfers and process validation campaigns. Prior to this, Mitchell held various positions at bluebird bio and Eli Lilly and Company, specializing in external manufacturing operations, process validation, and operational improvements. An accomplished author, Mitchell's work includes contributions to regulatory submissions and scientific publications, underpinned by a Bachelor of Science Degree in Chemical Engineering from the University of Virginia, earned with highest distinction.